Imperial College London to begin human testing of new Covid-19 vaccine

Modesto Morganelli
Giugno 16, 2020

He added: "If all goes well, we will have the results of the clinical trials in August/September".

"For any American who is vulnerable, who can not afford the vaccines, and desires the vaccine, we will provide it for free", a USA government official said during a call with reporters, requesting anonymity.

Rather than giving people a weakened form of the illness, the Imperial vaccine instead uses synthetic strands of genetic code based on the genetic material of Sars-CoV-2, the "novel coronavirus" responsible for the pandemic.

AstraZeneca is working on only one vaccine candidate out of more than 130 in development across the industry, but the team has quickly advanced to midstage testing with efficacy trials planned yet this year.

According to The Guardian's latest report, Imperial College London's researchers will begin testing the new coronavirus vaccine this week, which will be trialed in 300 people.

The Trump administration aims to narrow its financial support to about seven experimental coronavirus vaccines from the 14 it has been working with so far, the U.S. Department of Health and Human Services (HHS) said on Tuesday.

Scientists have never created vaccines from scratch this fast and it's far from clear that any will ultimately prove safe and effective.

Numerous governments have already signed deals with the drugmaker to order doses, including an agreement over the weekend from Italy, France, Germany and the Netherlands worth $843 million for 300 million doses.

An entrance to a Moderna, Inc., building, May 18, 2020, in Cambridge, Massachusetts.

The company announced last week that it will enter the third and final stage of its clinical trial in July with 30,000 participants.

Though four nations signed the deal, the vaccines are for all European Union member states, and the scheme allows other countries to join it under the same conditions, a source from the Italian health ministry told Reuters, adding China, Brazil, Japan and Russian Federation have expressed interest. Once the vaccine was proven effective, the researchers hope it will be administered to 6,000 volunteers. "That is the correct approach and it distributes the risk".

Since lockdowns and social-distancing measures have helped to keep infection rates low in many countries, some of the world's leading vaccine efforts are seeking to conduct phase III trial in active outbreaks to evaluate the effectiveness of their shots. US officials say they estimate some 20 million to 40 million Americans will already have antibodies to the virus and will be a lower priority for the first round of vaccines.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE